Zobrazeno 1 - 10
of 22
pro vyhledávání: '"David F. Claxton"'
Autor:
Raymond J. Hohl, Witold B. Rybka, Seema Naik, Shin Mineishi, W. Christopher Ehmann, Junjia Zhu, Natthapol Songdej, Hong Zheng, David F. Claxton, Chenchen Zhao, Joseph J. Drabick, Bei Jia
Publikováno v:
American Journal of Hematology
Autor:
Jeff Sivik, Chenchen Zhao, Natthapol Songdej, Todd D. Schell, Witold B. Rybka, David F. Claxton, Seema Naik, Hong Zheng, Ming Wang, W. Christopher Ehmann, Bei Jia, Raymond J. Hohl, Hui Zeng, Shin Mineishi
Publikováno v:
British Journal of Haematology
Summary Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine
Autor:
Pau Montesinos, Farhad Ravandi, Martha Arellano, Karen Seiter, Ellin Berman, Jessica K. Altman, Lori J. Maness, Donald P. Quick, Parameswaran Venugopal, Judy H. Chiao, Scott R. Solomon, Rakesh Gaur, Mikkael A. Sekeres, Maria R. Baer, Marc Buyse, Aleksandra Butrym, David A. Rizzieri, Stephen A. Strickland, Stuart L. Goldberg, Tapan M. Kadia, Marc Gautier, David F. Claxton, Gary J. Schiller, Gianluca Gaidano, Kebede H. Begna, Selina M. Luger, Hagop M. Kantarjian, Xavier Thomas
Publikováno v:
Cancer
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alt
Autor:
Suming Huang, Dhimant Desai, Cesar Aliaga, Pavan Kumar Dhanyamraju, Sadie Steffens, Melanie A. Ehudin, Morgann Klink, Yali Ding, Mohammad Atiqur Rahman, Chunhua Song, Preeti Bhadauria, Arati Sharma, Chandrika Gowda, David F. Claxton, Soumya Iyer
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Simple Summary Acute Myeloid Leukemia is an aggressive disease with poor outcomes. New targeted therapies that can boost the effects of currently used chemotherapy medications without added toxicity are needed. Targeting an overactive kinase, called
Autor:
Primo N. Lara, Mark Kirschbaum, Timothy W. Synold, David R. Gandara, David F. Claxton, Joseph Tuscano, Jasmine Zain, Paul Frankel, Edward M. Newman
Publikováno v:
British Journal of Haematology. 180:445-448
Autor:
David F. Claxton, Junjia Zhu, Jeffrey J. Pu, Michael G. Bayerl, Joyson Poulose, Jozef Malysz, Julie Fanburg-Smith
Publikováno v:
Br J Haematol
Autor:
Todd E. Fox, Su Fern Tan, David J. Feith, Brian M. Barth, Myles C. Cabot, Mark Kester, David F. Claxton, Samy A.F. Morad, Thomas P. Loughran
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1851:919-928
The triphenylethylene antiestrogen, tamoxifen, can be an effective inhibitor of sphingolipid metabolism. This off-target activity makes tamoxifen an interesting ancillary for boosting the apoptosis-inducing properties of ceramide, a sphingolipid with
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:41-46
Background Clofarabine, a second-generation nucleoside analogue, was studied in combination with etoposide and mitoxantrone in acute leukemia. Patients and Methods In the phase I portion of this study clofarabine was given 20 or 25 mg/m2 daily for 5
Autor:
D W Dougherty, David F. Claxton, Witold B. Rybka, Jeffrey Sivik, Christopher Ehmann, Joseph J. Drabick, Giampaolo Talamo
Publikováno v:
Bone Marrow Transplantation. 44:157-161
High-dose melphalan is considered the current standard of care among the preparative regimens used in peripheral blood autologous SCT (ASCT) for multiple myeloma (MM). We report the results of a single ASCT in 79 MM patients using the BU/CY condition
Autor:
Sergio Giralt, Susan O'Brien, Paolo Anderlini, M. Davis, Naoto T. Ueno, Borje S. Andersson, James Gajewski, Farhad Ravandi, Hagop M. Kantarjian, M. Korbling, David F. Claxton, M. Donato, A. Cohen, Issa F. Khouri, D. DeVos, Richard E. Champlin
Publikováno v:
Bone Marrow Transplantation. 27:1221-1225
Relapse after allogeneic progenitor cell transplant is associated with a poor prognosis for patients with advanced leukemia, with few curative options available. Use of novel chemotherapeutic agents with limited toxicity is warranted. We investigated